These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3061270)

  • 1. Transferable resistance to ceftazidime in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Verschraegen G; Vuye A; Claeys G
    Acta Clin Belg; 1988; 43(5):356-61. PubMed ID: 3061270
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae from Zagreb, Croatia.
    Bedenic B; Zagar Z
    J Chemother; 1998 Dec; 10(6):449-59. PubMed ID: 9876053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    Rice LB; Carias LL; Bonomo RA; Shlaes DM
    J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of a transferable SHV-5 type beta-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece.
    Vatopoulos AC; Philippon A; Tzouvelekis LS; Komninou Z; Legakis NJ
    J Antimicrob Chemother; 1990 Nov; 26(5):635-48. PubMed ID: 2079446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of major antibiotic resistance in Escherichia coli and Klebsiella pneumoniae in Singapore, USA and China using a limited set of gene targets.
    Ginn AN; Wiklendt AM; Zong Z; Lin RT; Teo JW; Tambyah PA; Peterson LR; Kaul K; Partridge SR; Iredell JR
    Int J Antimicrob Agents; 2014 Jun; 43(6):563-5. PubMed ID: 24721234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.
    Wiener J; Quinn JP; Bradford PA; Goering RV; Nathan C; Bush K; Weinstein RA
    JAMA; 1999 Feb; 281(6):517-23. PubMed ID: 10022107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of clinical multidrug-resistant Escherichia coli and Klebsiella pneumoniae isolates, 2007-2009, China.
    Zhang Y; Yang J; Ye L; Luo Y; Wang W; Zhou W; Cui Z; Han L
    Microb Drug Resist; 2012 Oct; 18(5):465-70. PubMed ID: 22548669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Bauernfeind A; Abele-Horn M; Emmerling P; Jungwirth R
    J Antimicrob Chemother; 1994 Dec; 34(6):1074-6. PubMed ID: 7730225
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations in
    Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary isolates of apramycin-resistant Escherichia coli and Klebsiella pneumoniae from Dublin.
    Johnson AP; Malde M; Woodford N; Cunney RJ; Smyth EG
    Epidemiol Infect; 1995 Feb; 114(1):105-12. PubMed ID: 7867728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel transferable extended-spectrum beta-lactamase (SHV-6) from Klebsiella pneumoniae conferring selective resistance to ceftazidime.
    Arlet G; Rouveau M; Bengoufa D; Nicolas MH; Philippon A
    FEMS Microbiol Lett; 1991 Jun; 65(1):57-62. PubMed ID: 1874404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.
    Wong-Beringer A; Hindler J; Loeloff M; Queenan AM; Lee N; Pegues DA; Quinn JP; Bush K
    Clin Infect Dis; 2002 Jan; 34(2):135-46. PubMed ID: 11740699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of CTX-M resistance marker and integrons among Escherichia coli and Klebsiella pneumoniae isolates of clinical origin.
    Shaikh S; Rizvi SM; Anis R; Shakil S
    Lett Appl Microbiol; 2016 May; 62(5):419-27. PubMed ID: 26997253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime resistance among Klebsiella pneumoniae in south India.
    Abigail S; Mathai E; Jesudason MV; John TJ
    Indian J Med Res; 1995 Aug; 102():53-5. PubMed ID: 8834813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of plasmid-mediated quinolone resistance determinants in Klebsiella pneumoniae and Escherichia coli from Tokai, Japan.
    Okade H; Nakagawa S; Sakagami T; Hisada H; Nomura N; Mitsuyama J; Yamagishi Y; Mikamo H
    J Infect Chemother; 2014 Dec; 20(12):778-83. PubMed ID: 25239060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.